Q-omics provides the consensus-scored SAP30L profile across patient tissues and cancer cell-line models. SAP30L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SAP30L is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, SAP30L protein abundance shows 26,357 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, THCA, and LUAD as cancer lineages where SAP30L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAP30L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAP30L survival associations across molecular data types. SAP30L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAP30L RNA expression–survival associations across cancer types. High SAP30L expression shows unfavorable associations in KICH and KIRP, but favorable associations in KIRC, HNSC, BLCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SAP30L RNA expression.
This table summarizes SAP30L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SAP30L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAP30L shows lower tumor expression in THCA, UCEC, LUSC, LUAD and COAD and higher tumor expression in LIHC. The THCA box plot shows higher SAP30L RNA expression in normal versus tumor tissue (log2 FC = −0.887, t-test p < 0.001).
This table shows molecular features associated with SAP30L in patient tissues and cancer cell lines. In patient samples, SAP30L shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SAP30L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
